Company intelligence / Profile preview

Innovative Molecules GmbH

Munich, Bavaria, Germanyinnovativemolecules.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Innovative Molecules is developing IM-250, a second-generation helicase primase inhibitor for the treatment of herpes simplex virus infections. Preclinical data suggest that IM-250 not only blocks active viral replication but may also reduce or eradicate the latent viral reservoir, potentially leading to fewer recurrences or even a cure. The company raised €20 million in Series A funding in June 2021 to advance IM-250 into Phase 2 clinical trials

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (specifically, helicase primase inhibitors)
Industry: Biotech

Drug pipeline

2 assets

adibelivir

1 more asset in the full pipeline.

Partnerships

LSP (Life Sciences Partners) as lead investor for Series A financing round

Beyond the preview

Go deeper on Innovative Molecules GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovative Molecules GmbH.